Floatz logo

Enavermotide

Carcinoma, Hepatocellular

Pharmexa A/SvaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

521 Active assets in the Carcinoma, Hepatocellular cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Enavermotide is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative ·
60 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →